Solveig Hofvind is head of the Section for Breast Cancer Screening at the Cancer Registry of Norway and of BreastScreen Norway, a nationwide screening program that invites women aged 50 to 69 to mammographic screening every other year.
As head of BreastScreen Norway, Solveig is responsible for the administration, quality assurance and development of the screening program. She has a strong focus on the operation of the program, both locally, and by the health trusts. She also has expertise in breast cancer and screening research, with a focus on epidemiology, risk, diagnosis, treatment, and prognosis.
She is currently an active supervisor and has supervised several doctoral and postdoctoral fellows.
Hofvind is a popular lecturer, both in Norway and internationally, on topics related to breast cancer screening. She is actively involved in a number of national and international research collaborations.
Hofvind is Professor of Radiography at OsloMet, and was a Visiting Professor at the University of Vermont in 2006-07 and 2010-11.
Solveig Hofvind is a trained breast radiographer and obtained her master’s degree (Norwegian: hovedfag) from the Norwegian School of Sports Sciences, where she researched physical activity and risk of breast cancer.
She was awarded a Dr. Philos from the University of Oslo in 2005. Her dissertation was titled The Norwegian Breast Cancer Screening Program: Selected Process Indicators and their Utilization in Epidemiological Research.
Hofvind leads, supervises and participates in a numerous research projects, including:
Projects in artificial intelligence:
- MIM: Machine learning in BreastScreen Norway
- Can artificial intelligence increase accuracy and effectiveness of breast cancer screening?
- BADDI: Artificial intelligence in screening with standard mammography and tomosynthesis
Development of breast cancer tumours
- How likely are benign breast disease and premalignant lesions to progress to invasive breast cancer?
- How quickly do breast cancers grow?
Tomosynthesis in breast cancer screening
- Overdiagnosis and underdiagnosis in BreastScreen Norwayt
- Breast compression in BreastScreen Norway
- Long-term effects following treatment of screen-detected versus symptomatic breast cancer
Sebuødegård S, Botteri E, Hofvind S (2020)
Breast Cancer Mortality After Implementation of Organized Population-Based Breast Cancer Screening in Norway
J Natl Cancer Inst, 112 (8), 839-846
DOI 10.1093/jnci/djz220, PubMed 31848605
Lilleborge M, Falk RS, Hofvind S (2020)
Number of prior negative screening outcomes does not influence future risk of breast cancer
Eur J Epidemiol, 35 (6), 549-556
DOI 10.1007/s10654-020-00645-0, PubMed 32430839
Tsuruda KM, Hofvind S, Akslen LA, Hoff SR, Veierød MB (2019)
Terminal digit preference: a source of measurement error in breast cancer diameter reporting
Acta Oncol, 59 (3), 260-267
DOI 10.1080/0284186X.2019.1669817, PubMed 31566467
Hoff SR, Myklebust TÅ, Lee CI, Hofvind S (2019)
Influence of Mammography Volume on Radiologists' Performance: Results from BreastScreen Norway
Radiology, 292 (2), 289-296
DOI 10.1148/radiol.2019182684, PubMed 31135295
Hofvind S, Holen ÅS, Aase HS, Houssami N, Sebuødegård S, Moger TA, Haldorsen IS, Akslen LA (2019)
Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial
Lancet Oncol, 20 (6), 795-805
DOI 10.1016/S1470-2045(19)30161-5, PubMed 31078459
Bhargava S, Akslen LA, Bukholm IRK, Hofvind S (2019)
Performance measures among non-immigrants and immigrants attending BreastScreen Norway: a population-based screening programme
Eur Radiol, 29 (9), 4833-4842
DOI 10.1007/s00330-019-6009-2, PubMed 30762109
Se alle publikasjoner på PubMed